BACKGROUND: Peptic ulcer and its treatments have been associated to pancreatic cancer risk, although the evidence is inconsistent. METHODS: We pooled 10 case-control studies within the Pancreatic Cancer Case-control Consortium (PanC4), including 4717 pancreatic cancer cases and 9374 controls, and estimated summary odds ratios (OR) using multivariable logistic regression models. RESULTS: The OR for pancreatic cancer was 1.10 [95% confidence interval (CI) 0.98-1.23] for history of ulcer (OR = 1.08 for gastric and 0.97 for duodenal ulcer). The association was stronger for a diagnosis within 2 years before cancer diagnosis (OR = 2.43 for peptic, 1.75 for gastric, and 1.98 for duodenal ulcer). The OR was 1.53 (95% CI 1.15-2.03) for history of gastrectomy; however, the excess risk was limited to a gastrectomy within 2 years before cancer diagnosis (OR = 6.18, 95% CI 1.82-20.96), while no significant increased risk was observed for longer time since gastrectomy. No associations were observed for pharmacological treatments for ulcer, such as antacids, H2-receptor antagonists, or proton-pump inhibitors. CONCLUSIONS: This uniquely large collaborative study does not support the hypothesis that peptic ulcer and its treatment materially affect pancreatic cancer risk. The increased risk for short-term history of ulcer and gastrectomy suggests that any such association is due to increased cancer surveillance.
BACKGROUND: Peptic ulcer and its treatments have been associated to pancreatic cancer risk, although the evidence is inconsistent. METHODS: We pooled 10 case-control studies within the Pancreatic Cancer Case-control Consortium (PanC4), including 4717 pancreatic cancer cases and 9374 controls, and estimated summary odds ratios (OR) using multivariable logistic regression models. RESULTS: The OR for pancreatic cancer was 1.10 [95% confidence interval (CI) 0.98-1.23] for history of ulcer (OR = 1.08 for gastric and 0.97 for duodenal ulcer). The association was stronger for a diagnosis within 2 years before cancer diagnosis (OR = 2.43 for peptic, 1.75 for gastric, and 1.98 for duodenal ulcer). The OR was 1.53 (95% CI 1.15-2.03) for history of gastrectomy; however, the excess risk was limited to a gastrectomy within 2 years before cancer diagnosis (OR = 6.18, 95% CI 1.82-20.96), while no significant increased risk was observed for longer time since gastrectomy. No associations were observed for pharmacological treatments for ulcer, such as antacids, H2-receptor antagonists, or proton-pump inhibitors. CONCLUSIONS: This uniquely large collaborative study does not support the hypothesis that peptic ulcer and its treatment materially affect pancreatic cancer risk. The increased risk for short-term history of ulcer and gastrectomy suggests that any such association is due to increased cancer surveillance.
Authors: R Talamini; J Polesel; S Gallus; L Dal Maso; A Zucchetto; E Negri; C Bosetti; E Lucenteforte; G Boz; S Franceschi; D Serraino; C La Vecchia Journal: Eur J Cancer Date: 2009-09-24 Impact factor: 9.162
Authors: Sara H Olson; Irene Orlow; Jennifer Simon; Diana Tommasi; Pampa Roy; Sharon Bayuga; Emmy Ludwig; Ann G Zauber; Robert C Kurtz Journal: Cancer Detect Prev Date: 2007-11-26
Authors: Ying Bao; Donna Spiegelman; Ruifeng Li; Edward Giovannucci; Charles S Fuchs; Dominique S Michaud Journal: Gastroenterology Date: 2009-10-07 Impact factor: 22.682
Authors: Dominique S Michaud; Mengyuan Ruan; Devin C Koestler; Dong Pei; Carmen J Marsit; Immaculata De Vivo; Karl T Kelsey Journal: JNCI Cancer Spectr Date: 2020-05-19
Authors: Kirstine K Søgaard; Dóra K Farkas; Lars Pedersen; Jennifer L Lund; Reimar W Thomsen; Henrik T Sørensen Journal: Cancer Med Date: 2016-02-29 Impact factor: 4.452